Uncategorized

GenKOre to Speak at ACCESS CHINA Partnering Forum

January 3rd, 2025 (Shanghai) — We are glad to announce that George Nam, the Chief Business Officer of GenKOre, will be presenting at the ACCESS CHINA Partnering Forum @ JPM on January 7th-9th, and 21st-23rd, 2025. ACCESS CHINA Biotech Forum is the largest corporate access event between Asia and the Western biopharma industry.

○ GenKOre has been developing CRISPR-Cas12f platform technology with mini-nuclease and proprietary gRNA, called as TaRGET (Tiny nuclease/augment RNA-based Genome Editing Technology) for over 15 years. Our TaRGET platform technology includes TaRGET-CUT (K/O), TaRGET-ABE (based editing), TaRGET-A/I (activation/inhibitor) and TaRGET-FREE (K/I), which are all deliverable by all-in-one AAV vector due to its hypercompact size vs CRISPR-Cas9. With these technologies, we are developing gene editing therapy for ocular, muscular, CNS and liver diseases.

○ We have a track record of signing the collaboration and license agreement with a US-based biotech company and a research collaboration agreement with Revvity recently.

■ https://www.prnewswire.com/news-releases/genkore-announces-collaboration-with-a-us-based-company-on-in-vivo-gene-editing-therapy-301725677.html 

■https://www.prnewswire.com/news-releases/genkore-announces-strategic-collaboration-with-revvity-to-develop-innovative-gene-therapy-treatments-302173587.html 

○ We are seeking for out-licensing (1) R&D pipelines (Ocular – LCA10, CNS – HD & SMA) or (2) CRISPR-Cas12f technology (IP) to CDMO/cell therapy companies and (3) collaborating with the companies for their delivery technology in CNS field. In this regard, I would like to have a partnering meeting with you at 2025 JPM.

■ Protein engineering, BS/MS/PhD in POSTECH (Pohang Univ. of Science & Technology)

■ Having more than 20 years of experience in the field of business development, commercialization & marketing

■ Working at local pharma companies, multinational pharma companies (Otsuka), and Samsung Bioepis (alliance manager for Biogen and Merck) and contributed to Biotech’s IPO such as TiumBio.

ACCESS CHINA Partnering Forum @ JPM is scheduled to be held on January 7th-9th, and 21st-23rd, 2025, via Zoom webinar. This event helps biotechs/pharmas efficiently present their assets in front of 500+ healthcare companies and VCs online. During the event, the audience can have access to innovative pharma and healthcare products from worldwide.

Conference Name: ACCESS CHINA Partnering Forum

Date & Time: January 7-9 (Live), and 21-23(VoD), 2025, China time

Content: Keynote Speeches, Panel Discussion, Company Presentations, ChemPartner-ACCESS CHINA Dinner Reception

Scale: Expected 500+ participants Online; 100 company roadshows

Participants: Pharma/Biotech senior management and BDs

View more information at https://biotochina.org/

To register for ACCESS CHINA online, please visit: ACCESS CHINA Biotech Forum

For more information, please contact:

Wendi Xiang

Wxiang@yafocapital.com